Analytical Data
-
Gene name
IL-10
- Application
-
Alternative Names
CSIF; IL10A; TGIF; Cytokine Synthesis Inhibitory Factor
-
Species
Chicken
-
Source
HEK293
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q6A2H4
-
Expression Region
Leu22~Lys175
-
Molecular Weight
20kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interleukin-10 (IL-10) is a crucial anti-inflammatory cytokine that plays a significant role in regulating immune responses and maintaining immune homeostasis. Its primary functions include the inhibition of pro-inflammatory cytokine production, modulation of macrophage activity, and promotion of B cell survival and differentiation. Given its immunosuppressive properties, IL-10 has garnered considerable attention in therapeutic research, particularly for conditions characterized by excessive inflammation, such as autoimmune diseases, chronic inflammatory disorders, and certain cancers. Recombinant IL-10 proteins have been engineered for potential clinical applications to harness these beneficial effects. Research into IL-10 recombinant proteins focuses on understanding their mechanisms of action, optimizing their pharmacokinetics, and evaluating their efficacy and safety in various disease models. Furthermore, innovations in protein engineering and delivery systems are being explored to enhance the bioavailability and therapeutic potential of IL-10, aiming to translate these findings into effective treatments for patients suffering from inflammatory and immune-related diseases.
